Advanced Solid Tumors CancerBIOAGE-CANNCT07035470
Biological Age Predicts 90-Day Mortality in Advanced Cancer
An observational study of Advanced Solid Tumors Cancer and Hospitalizations, run by Ankara Etlik City Hospital at 1 site in Turkey (Türkiye).
Trial summary
This retrospective study evaluates whether biological age, calculated using the PhenoAge model, predicts short-term outcomes in patients with advanced cancer who were hospitalized. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Advanced Solid Tumors Cancer, Hospitalizations
- What is being tested?
- PhenoAge-Based Biological Age Assessment
- Type of treatment
- Injection or infusion
- How many people
- 1,615 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 5 Nov 2022to 31 Dec 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: This study includes adult patients (≥18 years old) with advanced-stage solid tumors who were hospitalized at Etlik City Hospital, Turkey, between November 5, 2022, and December 31, 2024. Only patients with at least 48 hours of hospitalization and complete laboratory data necessary for PhenoAge calculation were included. The study population represents a real-world sample of hospitalized cancer patients at elevated risk of short-term adverse outcomes.
Who may be able to join
- Hospitalized in the Medical Oncology Department between November 5, 2022, and December 31, 2024
- Histologically confirmed advanced-stage (stage III-IV) solid tumors
- Age ≥18 years
- Hospital stay of at least 48 hours
- Actively receiving chemotherapy or received it within the last 6 months
- Availability of all 9 required laboratory tests (albumin, creatinine, glucose, CRP, lymphocyte %, MCV, RDW, ALP, WBC) for PhenoAge calculation during the first admission
- Patients with multiple hospitalizations who meet the inclusion criteria will be included
Who cannot join
- Elective hospitalizations (e.g., planned chemotherapy, biopsy)
- Patients who died during the first admission
- Missing required laboratory parameters
- ICU patients and unconscious patients
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Etlik City Hospital
Ankara, Yenimahalle, 06210
About this study
Official title: Biological Age as a Prognostic Marker in Hospitalized Patients With Advanced Cancer: A Retrospective Analysis Based on PhenoAge Model
This retrospective study evaluates whether biological age, calculated using the PhenoAge model, predicts short-term outcomes in patients with advanced cancer who were hospitalized. The main goal is to investigate associations between biological age and short-term mortality, functional status (ECOG), comorbidity burden (mCCI), and length of hospital stay. All data were collected from medical records without any patient intervention.
Read the detailed description
This is a retrospective observational study including hospitalized adult patients with stage III or IV solid tumors admitted to Etlik City Hospital between November 5, 2022 and December 31, 2024. Patients were included if they stayed for ≥48 hours and had all required laboratory values for calculating biological age using the Levine PhenoAge model. The study aimed to evaluate the association between biological age and (1) 30- and 90-day mortality, (2) ECOG performance score, (3) modified Charlson Comorbidity Index (mCCI), and (4) hospital length of stay. Regression and survival analyses were used to identify prognostic factors. All data were anonymized and collected retrospectively from hospital records.
- Conditions
- Advanced Solid Tumors Cancer, Hospitalizations
- Being tested
- PhenoAge-Based Biological Age Assessment
- Keywords
- Biological Age, PhenoAge, Advanced Cancer, Hospitalized Patients
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PhenoAge-Based Biological Age AssessmentOther
Biological age was retrospectively calculated using the PhenoAge algorithm, based on nine routine laboratory parameters and chronological age. This model estimates phenotypic aging and was used to predict short-term outcomes including mortality, functional status, comorbidity burden, and hospital length of stay. No new intervention was administered; all data were collected from existing medical records.
| Study group | Role | What they receive |
|---|---|---|
| Hospitalized Advanced Cancer Patients | Patients hospitalized with advanced solid tumors (Stage III or IV) in the oncology clinic were retrospectively analyzed. Biological age was calculated using the PhenoAge model. Clinical outcomes such as mortality, ECOG score, mCCI, and length of stay were assessed. Receives: Other: PhenoAge-Based Biological Age Assessment |
What is being measured
The primary outcome is the main question the study is designed to answer.
90-Day All-Cause Mortality
All-cause mortality within 90 days following the date of hospital admission (index hospitalization).
Measured: Up to 90 days post-admission
Secondary outcomes (1)
Modified Charlson Comorbidity Index (mCCI)
The Modified Charlson Comorbidity Index (mCCI) is a validated scoring system used to quantify comorbidity burden. It includes 19 comorbid conditions with weighted values and incorporates age adjustment. Scores range from 0 to 33. In this study, age points are added only for patients aged 50 years and above: +1 point for ages 50-59, +2 for 60-69, +3 for 70-79, and +4 for ≥80.
Higher mCCI scores indicate greater comorbidity burden and are associated with poorer clinical outcomes. The score is calculated retrospectively from documented diagnoses in the medical records at baseline.
Measured: Baseline (Day of hospital admission)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jun 2025
- Study start5 Nov 2022
- Primary completion31 Dec 2024
- Study completion31 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Advanced Solid Tumors CancerStudies of the same condition, open and under way.
- More trials run by Ankara Etlik City HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 1,615 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ankara Etlik City Hospital
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Galip Can Uyar, Ankara Etlik City Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07035470
- Sponsor's protocol ID
- AEŞH-BADEK-2025-0149
- Acronym
- BIOAGE-CAN
- Status last verified
- Jun 2025
- First submitted
- 16 Jun 2025
- Last updated
- 29 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Biological Age as a Prognostic Marker in Hospitalized Patients With Advanced Cancer: A Retrospective Analysis Based on PhenoAge Model
- ClinicalTrials.gov ID
- NCT07035470
- Acronym / sponsor ID
- BIOAGE-CAN / AEŞH-BADEK-2025-0149
- Conditions
- Advanced Solid Tumors Cancer, Hospitalizations
- Keywords
- Biological Age, PhenoAge, Advanced Cancer, Hospitalized Patients
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,615 participants (actual)
- Lead sponsor
- Ankara Etlik City HospitalOther government
- Study start
- 5 Nov 2022 (actual)
- Primary completion
- 31 Dec 2024 (actual)
- Study completion
- 31 Dec 2024 (actual)
- First posted
- 25 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This retrospective study evaluates whether biological age, calculated using the PhenoAge model, predicts short-term outcomes in patients with advanced cancer who were hospitalized. The main goal is to investigate associations between biological age and short-term mortality, functional status (ECOG), comorbidity burden (mCCI), and length of hospital stay. All data were collected from medical records without any patient intervention.
Detailed description
This is a retrospective observational study including hospitalized adult patients with stage III or IV solid tumors admitted to Etlik City Hospital between November 5, 2022 and December 31, 2024. Patients were included if they stayed for ≥48 hours and had all required laboratory values for calculating biological age using the Levine PhenoAge model. The study aimed to evaluate the association between biological age and (1) 30- and 90-day mortality, (2) ECOG performance score, (3) modified Charlson Comorbidity Index (mCCI), and (4) hospital length of stay. Regression and survival analyses were used to identify prognostic factors. All data were anonymized and collected retrospectively from hospital records.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Hospitalized Advanced Cancer Patients | – | Other: PhenoAge-Based Biological Age AssessmentPatients hospitalized with advanced solid tumors (Stage III or IV) in the oncology clinic were retrospectively analyzed. Biological age was calculated using the PhenoAge model. Clinical outcomes such as mortality, ECOG score, mCCI, and length of stay were assessed. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- This study includes adult patients (≥18 years old) with advanced-stage solid tumors who were hospitalized at Etlik City Hospital, Turkey, between November 5, 2022, and December 31, 2024. Only patients with at least 48 hours of hospitalization and complete laboratory data necessary for PhenoAge calculation were included. The study population represents a real-world sample of hospitalized cancer patients at elevated risk of short-term adverse outcomes.
Key inclusion criteria (7 listed)
- Hospitalized in the Medical Oncology Department between November 5, 2022, and December 31, 2024
- Histologically confirmed advanced-stage (stage III-IV) solid tumors
- Age ≥18 years
- Hospital stay of at least 48 hours
- Actively receiving chemotherapy or received it within the last 6 months
Key exclusion criteria (4 listed)
- Elective hospitalizations (e.g., planned chemotherapy, biopsy)
- Patients who died during the first admission
- Missing required laboratory parameters
- ICU patients and unconscious patients
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PhenoAge-Based Biological Age AssessmentBiological age was retrospectively calculated using the PhenoAge algorithm, based on nine routine laboratory parameters and chronological age. This model estimates phenotypic aging and was used to predict short-term outcomes including mortality, functional status, comorbidity burden, and hospital length of stay. No new intervention was administered; all data were collected from existing medical records. | Other | Hospitalized Advanced Cancer Patients |
Primary outcome
90-Day All-Cause Mortality
Time frame: Up to 90 days post-admission
All-cause mortality within 90 days following the date of hospital admission (index hospitalization).
1 secondary outcome
Modified Charlson Comorbidity Index (mCCI)
Time frame: Baseline (Day of hospital admission)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jun 2025.
- Individual participant dataSharing planned: No
Related trials for Advanced Solid Tumors Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor
Neoplasms
RecruitingPhase 1/2
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Advanced Solid Tumors Cancer and Hospitalizations, run by Ankara Etlik City Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
90-Day All-Cause Mortality (time frame: Up to 90 days post-admission). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jun 2025.